Last reviewed · How we verify
Cord blood
Cord blood is a source of hematopoietic stem cells and progenitor cells that can differentiate into various blood cell types and immune cells for therapeutic transplantation.
Cord blood is a source of hematopoietic stem cells and progenitor cells that can differentiate into various blood cell types and immune cells for therapeutic transplantation. Used for Acute leukemia in remission, Chronic leukemia, Myelodysplastic syndrome.
At a glance
| Generic name | Cord blood |
|---|---|
| Also known as | Vaccine, Umbilical cord blood |
| Sponsor | New York Medical College |
| Drug class | Hematopoietic stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | FDA-approved |
Mechanism of action
Umbilical cord blood contains CD34+ hematopoietic stem cells capable of self-renewal and multilineage differentiation into myeloid, lymphoid, and erythroid lineages. When cryopreserved and transplanted, these cells can reconstitute hematopoietic and immune function in patients with hematologic malignancies, inherited metabolic disorders, and immunodeficiencies. The therapeutic benefit derives from the stem cells' ability to engraft in bone marrow and restore normal blood cell production.
Approved indications
- Acute leukemia in remission
- Chronic leukemia
- Myelodysplastic syndrome
- Lymphoma
- Multiple myeloma
- Inherited metabolic disorders
- Severe aplastic anemia
- Severe combined immunodeficiency
Common side effects
- Graft-versus-host disease (GVHD)
- Graft failure or delayed engraftment
- Infection
- Hemorrhage
- Organ toxicity
Key clinical trials
- Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn
- Cord Blood Preptin Levels in Infants (NA)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity (NA)
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (PHASE1, PHASE2)
- Evaluation Of Cost-Effectiveness Of Iliac Branch Endoprostheses
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cord blood CI brief — competitive landscape report
- Cord blood updates RSS · CI watch RSS
- New York Medical College portfolio CI